Handelsavisen
prelaunch
Companies Healthcare 382150.KQ
38
382150.KQ KOSDAQ Biotechnology & Medical Research

382150.Kq

$4 640,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
55,8B KRW
P/E
EV / Rev
Div yield
0,00 %
Op margin
-6 246,4 %
ROE
-33,4 %
Net margin
-5 866,8 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-33,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 382150.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 382150.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 10,808,834,910, which is significantly higher than its total liabilities of KRW 650,874,290, resulting in a current ratio of 24.47. The price-to-book ratio of 5.27 and a debt-to-equity ratio of 0.01 indicate a low financial leverage and a strong equity base.

    Profitability metrics are negative, with a return on equity of -33.35% and a return on assets of -32.05%, reflecting a substantial net loss of KRW 5,369,587,680. These figures are well below the industry median for profitability, suggesting the company is underperforming in terms of generating returns on its equity and assets.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if the segment faces challenges.

    The company is currently experiencing a significant decline in performance, with a net loss of KRW 5,369,587,680 and a negative operating income of KRW 5,716,983,610. These figures suggest a challenging growth trajectory, with no clear signs of improvement in the near term.

    Risk factors include a high liquidity risk due to negative operating and free cash flows, although the company's strong cash reserves mitigate this to some extent. The risk of dilution is currently low, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow could necessitate future equity issuance, which would increase dilution risk.

    Recent events include the publication of the latest financial report, which highlights the company's significant net loss and negative operating income. No recent filings or transcripts indicate any major strategic shifts or new product launches that could alter the company's trajectory.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 24.47 and a debt-to-equity ratio of 0.01.
    • Profitability is severely negative, with a return on equity of -33.35% and a return on assets of -32.05%.
    • The company's revenue is concentrated in a single business segment, increasing operational risk.
    • The company is experiencing a significant decline in performance, with a net loss of KRW 5,369,587,680.
    • Liquidity risk is high due to negative operating and free cash flows, although strong cash reserves provide some buffer.
    • The risk of dilution is currently low, but the company's financial performance could necessitate future equity issuance.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $4 640,00
    Market cap
    $84.92B
    Enterprise value
    $74.23B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    5.3x
    P / Tangible book
    5.3x
    Tangible book
    $16.10B
    Net cash
    $10.69B
    Current ratio
    24.5
    Debt / equity
    0.0
    ROA
    -32.0%
    ROE
    -33.4%
    Cash conversion
    107.0%
    CapEx / revenue
    -27.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-6 246,4 %Bottom quartile
    Net Margin-5 866,8 %Bottom quartile
    ROE-33,4 %Below median
    Capex / Rev-27,0 %Below median
    D/E0,01Above median
    Cash Conv1,07Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 382150.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    382150.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage